BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Heart failure clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for heart failure: 302 (173 sponsors; 44 newly posted in the last 180 days, 9 stopped in the last 180 days; 21 new-entrant sponsors). Momentum score 9.9, rank 71 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 19, Phase 2 37, Phase 3 32, Phase 4 2, N/A 212.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
AstraZeneca AZN9NA 5, P3 3, P4 122
Novo Nordisk A/S NVO8P3 3, P2 3, P1 213
Tenax Therapeutics, Inc. TENX3P3 300
Bayer6NA 4, P3 201
Boehringer Ingelheim4NA 2, P3 200
Novartis Pharmaceuticals NVS4NA 1, P1 1, P3 201
Merck Sharp & Dohme LLC MRK3P3 2, P2 110
HELP Therapeutics Co., Ltd.4P2 3, P3 100
Eli Lilly and Company LLY3P2 1, P3 1, P1 110
Tasly Pharmaceutical Group Co., Ltd3P3 1, P2 212
Cytokinetics CYTK2P3 1, P2 100
Amgen AMGN1P3 100
Applied Therapeutics, Inc. AMAT1P3 100
Ascendis Pharma A/S ASND1P3 100
Biopeutics Co., Ltd1P3 100
Braveheart Bio, Inc. BRVE new entrant1P3 110
CSL Behring1P3 100
Pharmacosmos A/S1P3 100
Pierre Fabre Medicament1P3 100
Pulnovo Medical (Wuxi) Co., Ltd.1P3 100
Seismic Pharmaceuticals Operations LLC1P3 100
X4 Pharmaceuticals XFOR1P3 100
Abbott Medical Devices8NA 813
Edwards Lifesciences EW6NA 612
Impulse Dynamics6NA 600

New-entrant sponsors: Braveheart Bio, Inc..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-24 est.P2Tectonic Therapeutic TECXNCT06616974 A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)Pulmonary Hypertension; Heart Failure With Preserved Ejection Fractionactive not recruiting191
2026-12 est.P1/P2Iperboreal Pharma SrlNCT03994874 Peritoneal Ultrafiltration in Cardio Renal Syndrome.Congestive Heart Failurerecruiting84
2026-12 est.P1/P2BioCardia, Inc. BCDANCT05925608 Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem CellsHeart Failure, Systolicactive not recruiting39
2026-12 est.P2Shandong Suncadia Medicine Co., Ltd.NCT06820099 Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and ObesityAdults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesirecruiting225
2026-12 est.P2Cardiac SuccessNCT06851949 Vsling™ I: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients With Heart FailureHeart Failure With Reduced Ejection Fractionrecruiting20
2026-12-14 est.P2Bristol-Myers Squibb BMYNCT06122779 Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)Heart Failureactive not recruiting227
2026-12-31 est.P2Tasly Pharmaceutical Group Co., LtdNCT06669169 Efficacy and Safety of Jia Shen Tablets in Chronic Heart FailureHeart Failurenot yet recruiting288
2026-12-31 est.P1/P2Tasly Pharmaceutical Group Co., LtdNCT07265349 A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart FailureCoronary Artery Bypass Grafting (CABG); Chronic Heart Failure; Chronic Ischemic Cardiomyopathyrecruiting51
2026-12-31 est.P2Sinotau Pharmaceutical GroupNCT07443696 PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic CardiomyopathyIschemic Cardiomyopathy; Heart Failurerecruiting40

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-10 est.P1/P2HELP Therapeutics Co., Ltd.NCT06340048 Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart FailureHeart Failureactive not recruiting36
2026-10-31 est.P2Salubris Biotherapeutics IncNCT06369298 Study of JK07 in Patients With Chronic Heart FailureHeart Failure With Reduced Ejection Fraction; Heart Failure With Preserved Ejection Fractionactive not recruiting282
2026-10-31 est.P2AskBio IncNCT05598333 Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart FailureCongestive Heart Failureactive not recruiting150
2026-10-01 est.P3Novo Nordisk A/S NVONCT06200207 A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationHeart Failure; Systemic Inflammationactive not recruiting673
2026-09-24 est.P2Innovent Biologics (Suzhou) Co. Ltd.NCT06862908 A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityObesity; Heart Failure With Preserved Ejection Fraction (HFPEF); Heart Failure With Mildly Reduced Eactive not recruiting141
2026-09-03P3Novo Nordisk A/S NVONCT05636176 A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationHeart Failureterminated4874
2026-09 est.P2Fujian Shengdi Pharmaceutical Co., Ltd.NCT07318103 Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid RetentionFluid Retention Caused by Heart Failurerecruiting153
2026-09 est.P2Cytokinetics CYTKNCT06793371 AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEFSymptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)recruiting60
2026-08-30P1/P2Implicit BioscienceNCT06556810 IC14 for Treatment of Acute Decompensated Heart FailureAcute Decompensated Heart Failurecompleted10

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "heart failure"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.